Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care.
Julian D Gillmore, Katrin Hahn, J Gustav Smith...
https://pubmed.ncbi.nlm.nih.gov/40108078/Actively Recruiting
Led by AstraZeneca · Updated on 2026-09-09
52121
Participants Needed
29
Research Sites
N/A
Total Duration
This observational study focuses on patients with ATTR amyloidosis, aiming to gather real-world data on their disease journeys before and after diagnosis. It seeks to describe patient characteristics, treatment patterns, and outcomes, including clinical, economic, and quality of life measures. The study also aims to better understand how ATTR amyloidosis presents and affects daily living. The study does not involve any interventions, as it is a retrospective analysis of existing data from multiple countries. It includes patients with various types of ATTR amyloidosis, such as cardiomyopathy, neuropathy, wild type, hereditary, and mixed phenotypes. Data collected cover the period from before diagnosis up to the end of follow-up, which can last up to 12 years. Participants medical records will be reviewed to assess healthcare resource use, clinical measurements like neuropathy impairment scores, and humanistic outcomes such as quality of life and activities of daily living. The study will evaluate hospitalizations, outpatient visits, emergency visits, transplant events, and mortality over time. This long-term data collection helps characterize disease impact and resource use for patients with ATTR amyloidosis.
CONDITIONS
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote record review)
Duration - Up to 12 years
Researchers collect and analyze existing medical records and data on patient characteristics, treatments, healthcare use, and clinical outcomes over time.
No visits required; data collected retrospectively and prospectively from records
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Julian D Gillmore, Katrin Hahn, J Gustav Smith...
https://pubmed.ncbi.nlm.nih.gov/40108078/Kevin M Alexander, Shun Kohsaka, Steen Hvitfeldt Poulsen...
https://pubmed.ncbi.nlm.nih.gov/42201638/AstraZeneca
Lead Sponsor